January 25, 2023, Vancouver, British Columbia: Gemina Laboratories Ltd. (CSE: GLAB) (FRA:8I7) (the “Company” or “Gemina”) is delighted to announce the appointment of Dr. Bola Grace to the Board of Directors.
Dr. Grace brings extensive leadership experience in the biotech/healthcare industry to the Board, having provided strategic, commercial and technical direction on many complex programmes, delivering numerous award-winning diagnostic products to the consumer marketplace.
With a career that started in R&D at Unipath she went on to hold a Lead Scientist role at Alere before becoming Head of R&D Programme for Swiss Precision Diagnostics (“SPD”) (a global leader in reproductive health testing, jointly owned by Abbott Laboratories and Proctor and Gamble). She is a passionate believer in inclusive, user-centric design, not least because of its impact on healthcare equity, and holds a prestigious visiting professorship in this field with the UK’s Royal Academy of Engineering.
Dr. Grace has always succeeded in balancing her private sector career with her academic interests. Beyond her current visiting professorship with the Royal Academy of Engineering, she previously held a 3-year visiting faculty position at Kings College London and nearly a decade of engagement with University College London (“UCL”), initially with the Elizabeth Garrett Anderson Institute for Women’s Health, and more recently with UCL’s Global Business School for Health. She has Bachelor and Master’s degrees in Biotechnology and Molecular Biology and a Ph.D. from UCL in Population Health and Epidemiology. She also holds an Executive MBA from the University of Cambridge Judge Business School. She is a Fellow of the Royal Society of Public Health, Fellow of the Higher Education Academy, and a Chartered Fellow of the Chartered Management Institute.
Brian Firth, CEO of Gemina, stated, “I had the pleasure of working with Bola while at SPD. She is an outstanding driver of processes that convert exceptional science into product families. In the product development cycle, she is unmatched in her focus on designing products and services in partnership with the people who will use them – a product philosophy which will be a key differentiating factor as Gemina continues to build its respiratory disease product offerings.”
“Gemina’s technology platform brings some of the most significant inventions to Point of Care Diagnostics since Lateral Flow Assays were invented,” commented Dr. Bola Grace. “We share a common philosophy that inclusive design matched with rigorous quality management is essential to the democratization of diagnostics. I am looking forward to helping Gemina steer a course towards quality, equitable healthcare for people around the world.”
With Dr. Grace’s appointment to the Board, the Company also announces that Dr. James Tansey has resigned from his directorship of Gemina. James has been a member of Gemina’s leadership group since its inception and has played an essential role in the Company’s launch, public listing and subsequent successes. James will continue to serve the Company as an advisor.
“James has been a wonderful servant of Gemina,” stated Board Chairman John Davies. “His departure is part of a planned maturation of the Board, focused on bringing deep sectorial experience to the Company – a strategy that James helped design for Gemina. On behalf of the Company generally, I’d like to express a deep appreciation for all of James’ work over the last 3 years.”
About Gemina Laboratories Ltd.
Gemina Labs is a biosensor and diagnostic company with a transformative, patented, proprietary chemistry that powers next-generation testing platforms for a wide range of pathogens that affect human health and wellness. Our technology drives testing platforms that are fast, affordable and accurate, and easily self-administered. Our development pipeline includes platforms for the rapid testing of COVID-19, influenza and other viruses. Additional information on the Company can be found at www.geminalabs.com.
About Syniad Innovations
Syniad Innovations is a company focused on building breakthrough deep tech companies around cutting-edge advances in science & engineering, like quantum networking.
Syniad addresses some of the world’s most pressing challenges by collaborating with exceptional researchers and provides the expertise, capital, and networks to help accelerate their ideas into important new products and services. Founded in 2015 in Vancouver, Syniad possesses a unique pedigree in research commercialization.
Our experience includes projects with various stakeholders, from Fortune 500 companies to governments and universities that want a step change in impact.